logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
L

Lihua E. Budde

city of hope national medical center
H指数:39
被引数:8,213

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health-related quality of life with mosunetuzumab plus polatuzumab vedotin in R/R LBCL: Phase 3 SUNMO trial

mosunetuzumab联合polatuzumab vedotin在R/R LBCL中的健康相关生活质量：III期SUNMO试验

Clinical Lymphoma Myeloma and Leukemia
IF2.7
2026-10-120
OAAI
Won-Seog Kim; Huilai Zhang; Dai Maruyama; Astrid Pavlovsky; Eduardo M. Rego; Huangming Hong; Hideki Goto; Mark Fesler; Boone Goodgame; Zhiming Li; Adam J. Olszewski; Joan Ashby; Shen Yin; Wahib S. Ead; Martin Janousek; Song Pham; Connie L. Batlevi; Michael C. Wei; Jason Westin; Lihua E. Budde
B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy

B细胞活化因子受体在B淋巴母细胞白血病中的表达：流式细胞术分析及其靶向治疗意义

British Journal of Haematology
IF3.8
2026-08-210
PRE
Parastou Tizro; Ibrahim Aldoss; Xiuli Wang; Larry W. Kwak; Zhenyuan Dong; Kevin Arango; Michael Palmer; Soungchul Cha; Jessica Hughes; Huiyan Ma; Vinod Pullarkat; Elizabeth Budde; Guido Marcucci; Winston Lee; Lorinda Soma; Stephen Forman; Joo Y. Song
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter’s transformation.

Mosunetuzumab单药治疗在复发/难治性Richter’s transformation患者中是有效的且可耐受的。

Blood Advances
IF7.1
2026-02-090
OAAI
Katharine Louise Lewis; Sarit E Assouline; Ross Baker; Nancy L Bartlett; Dima El-Sharkawi; Pratyush Giri; Matthew Ku; Matthew Matasar; Stephen Schuster; John Radford; Michael C Wei; Shen Yin; Antonia Kwan; Iris To; Vibya Raghavan; Lihua E Budde; Chan Y Cheah
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial

Axicabtagene ciloleucel联合利妥昔单抗治疗难治性大b细胞淋巴瘤: 2期单臂ZUMA-14试验

Nature Cancer
IF28.5
2026-01-050
OAAI
Paolo Strati; Lori Leslie; Parveen Shiraz; Lihua E. Budde; Olalekan O. Oluwole; Matthew Ulrickson; Aravind Ramakrishnan; Teresa Zhang; Jennifer Sun; Francesca Milletti; Justyna Kanska; Rhine Shen; Frank Neumann; Hairong Xu; Krish Patel
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis

Blinatumomab/Lenalidomide治疗复发/难治性B细胞淋巴瘤的I期研究；毒性、疗效及相关性分析

Blood Advances
IF7.1
2025-11-120
OAAI
Joseph M. Tuscano; Tamer Othman; Paul Frankel; Christopher Ruel; Christina Poh; Samantha Herbert; Emanual Maverakis; Alexander A. Merleev; Guillaume Luxardi; Mehrdad Abedi; Raghuveer Ranganathan; Dipenkumar Modi; Jasmine Zain; Elizabeth L. Budde; Matthew Mei; Aaron S Rosenberg; Rasmus T Hoeg; Caitlin Costello; Francine M. Foss; Basem M. William
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study

Mosunetuzumab对复发/难治性滤泡性淋巴瘤的老年患者具有疗效且耐受性良好：一项I/II期研究的亚组分析

BRITISH JOURNAL OF HAEMATOLOGY
IF3.8
2025-11-010
OAAI
Thiruvengadam, Swetha Kambhampati; Popplewell, Leslie L.; Herrera, Alex F.; Mei, Matthew; Nikolaenko, Liana; Zuo, Xiaofang; Yin, Shen; Zhou, Mingzhu; Mun, Yong; Wu, Mei; Wei, Michael C.; Budde, Lihua E.
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration

Polatuzumab vedotin在CNS淋巴瘤中的应用：关于血脑屏障穿透的可行性研究

Blood Advances
IF7.1
2025-10-100
OAAI
Lei Gao; Avyakta Kallam; Geoffrey Shouse; John H. Baird; Stacy Pak; Yue Qin; Joo Y. Song; Guido Marcucci; Lucy Y. Ghoda; Claire Guillen; Suk-Joon Hyung; Ola M. Saad; Helen Davis; Randall Dere; Connie L. Batlevi; Joshua Meinert; Lihua E. Budde; Alexey V. Danilov; Alex F. Herrera; Larry W. Kwak; Stephen J. Forman; James K. Godfrey
B-Cell Lymphomas 3.2025 Featured Updates to the NCCN Guidelines

B细胞淋巴瘤 3.2025 NCCN指南特色更新

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
IF16.4
2025-10-010
PRE
Zelenetz, Andrew D.; Gordon, Leo I.; Abramson, Jeremy S.; Advani, Ranjana H.; Andreadis, Babis; Bartlett, Nancy L.; Budde, L. Elizabeth; Caimi, Paolo F.; Chang, Julie E.; Christian, Beth; DeVos, Sven; Dholaria, Bhagirathbhai; Fayad, Luis E.; Habermann, Thomas M.; Hamid, Muhammad Saad; Hernandez-Ilizaliturri, Francisco; Hu, Boyu; Karimi, Yasmin; Kelsey, Christopher R.; King, Rebecca; Kline, Justin; Krivacic, Susan; Lacasce, Ann S.; Landsburg, Daniel; Lim, Megan; Messmer, Marcus; Rabinovitch, Rachel; Ramakrishnan, Praveen; Reid, Erin; Roberts, Kenneth B.; Saeed, Hayder; Saito, Naoyuki G.; Smith, Stephen D.; Swinnen, Lode J.; Tuscano, Joseph; Vose, Julie M.; Dwyer, Mary; Sundar, Hema
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

国际共识指南：关于AML CAR T细胞临床研究的实施与报告

Blood Advances
IF7.1
2025-08-210
OAAI
Swati Naik; Richard Aplenc; Susanne H.C. Baumeister; Marco Becilli; Anand S. Bhagwat; Challice L. Bonifant; Lihua E. Budde; Christopher D. Chien; Kevin J. Curran; Anthony F. Daniyan; Alexandra Dreyzin; Rebecca A. Gardner; Sara Ghorashian; Stephen Gottschalk; LaQuisa C. Hill; M. Eric Kohler; Adam Lamble; Franco Locatelli; Maksim Mamonkin; Bilal Omer
Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

门诊Brexucabtagene autoleucel在B细胞急性淋巴细胞白血病和套细胞淋巴瘤中的应用

American Journal of Hematology
IF9.9
2025-08-200
PREAI
Tamer Othman; John H. Baird; Yan Wang; Stacy Pak; Hannah Zhong; Ibrahim Aldoss; Ji-Lian Cai; Alexey Danilov; Tycel J. Phillips; Vaibhav Agrawal; Karamjeet S. Sandhu; Matthew Mei; Paul B. Koller; Joycelynne Palmer; Stephen J. Forman; Lihua E. Budde; Ahmed Aribi
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis

Brexucabtagene autoleucel治疗复发或难治性套细胞淋巴瘤的实效结果：一项CIBMTR分析

Blood Advances
IF7.1
2025-07-280
OAAI
Nausheen Ahmed; Swetha Kambhampati Thiruvengadam; Mehdi Hamadani; Zhen-Huan Hu; Natalie Grover; Mazyar Shadman; Frederick L. Locke; James Gerson; Matthew J. Frank; Lihua E. Budde; Michael Wang; Soyoung Kim; Matthew Bye; Mohamed A. Kharfan-Dabaja; Craig Sauter; Peiman Hematti; Cameron J. Turtle; Sairah Ahmed; Amy Moskop; Brent Logan; Ana Nunes; David Dalton; Ioana Kloos; Daniel Lee; Hairong Xu; Marcelo C. Pasquini; Alex F. Herrera
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma

与新生侵袭性大b细胞淋巴瘤相比，CD19 CAR T在转化的惰性淋巴瘤中的结果

AMERICAN JOURNAL OF HEMATOLOGY
IF9.9
2024-12-230
OAAI
Thiruvengadam, Swetha Kambhampati; Merryman, Reid; Wang, Yan; Gaulin, Charles; Bezerra, Evandro; Voorhees, Timothy; Seshadri, Madhav R.; Falade, Ayo; Habib, Alma; Ayers, Amy A.; Bailey, Megumi; Brown, Annette; Bailey, Neil; Patel, Krish; Andreadis, Charalambos B.; Kittai, Adam S.; Jacobson, Caron; Palmer, Joycelynne; Forman, Stephen J.; Nastoupil, Loretta; Budde, Lihua E.
Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Mosunetuzumab单药治疗在重度预治疗复发或难治性套细胞淋巴瘤患者中显示出令人鼓舞的疗效和可管理的安全性。

BLOOD
IF23.1
2024-11-051
PRE
Budde, Elizabeth; Matasar, Matthew; Sehn, Laurie H.; Assouline, Sarit E.; Kuruvilla, John; Flinn, Ian W.; Yoon, Sung-Soo; Bosch, Francesc; Greenwald, Daniel; Gutierrez, Norma C.; Tzachanis, Dimitrios; Marlton, Paula; Mcguirt, Delaney; Yin, Shen; Wei, Michael C.; Kwan, Antonia; Tracy, Samuel; Penuel, Elicia; Bartlett, Nancy L.
Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

急性淋巴细胞白血病（ALL）和套细胞淋巴瘤（MCL）门诊输注Brexucabtagene Autoleucel（brexu-cel）安全且可行

BLOOD
IF23.1
2024-11-050
PRE
Othman, Tamer; Baird, John H.; Wang, Yan; Pak, Stacy; Aldoss, Ibrahim; Cai, Ji-Lian; Danilov, Alexey; Phillips, Tycel J.; Agrawal, Uaibhav; Sandhu, Karamjeet S.; Mei, Matthew; Koller, Paul B.; Palmer, Joycelynne Michelle; Forman, Stephen J.; Budde, Lihua E.; Aribi, Ahmed
Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data

利用真实世界数据表征接受利妥昔单抗联合吉西他滨和奥沙利铂（R-GemOx）治疗复发或难治性弥漫大B细胞淋巴瘤的美国患者人群

BLOOD
IF23.1
2024-11-050
PRE
Budde, Lihua E.; Olszewski, Adam J.; Hu, Bei; Shah, Nikesh; Batlevi, Connie Lee; Yin, Shen; To, Iris; Wei, Michael C.; Kallemeijn, Martine; Orellana-Noia, Victor; Musick, Lisa; Shamas, Natasha; Pal, Navdeep; Shewade, Ashwini; Westin, Jason R.
A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

一项Loncastuximab Tesirine联合Mosunetuzumab治疗复发/难治性弥漫大B细胞淋巴瘤的II期研究

BLOOD
IF23.1
2024-11-050
PRE
Kambhampati, Swetha; Kallam, Avyakta; Borogovac, Azra; Chen, Lu; Puverel, Sandrine; Johnson, Jennifer; Melgar, Ivana; Baird, John H.; Danilov, Alexey; Godfrey, James; Khan, Niloufer; Mei, Matthew; Phillips, Tycel J. J.; Siddiqi, Tanya; Shouse, Geoffrey; Zain, Jasmine; Kwak, Larry W.; Rosen, Steven T.; Forman, Stephen J.; Song, Joo Y.; Herrera, Alex F.; Budde, Elizabeth
Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥ 2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Mosunetuzumab 在接受 ≥ 2 种既往治疗（包括有 POD24 病史者）的复发性和/或难治性滤泡性淋巴瘤患者中持续显示出具有临床意义的结果：一项关键性 II 期研究的 4 年随访结果

BLOOD
IF23.1
2024-11-051
PRE
Shadman, Mazyar; Bartlett, Nancy L.; Matasar, Matthew; Schuster, Stephen J.; Assouline, Sarit E.; Sehn, Laurie H.; Kuruvilla, John; Giri, Pratyush; Cheah, Chan Y.; Dietrich, Sascha; Fay, Keith; Ku, Matthew; Nastoupil, Loretta; Wei, Michael C.; Yin, Shen; Ma, Connie Y.; Tracy, Samuel; Kwan, Antonia; Penuel, Elicia; Budde, L. Elizabeth

研究方向

暂未获取到该数据
S
Stephen J. Forman
H 指数:127论文数:1,786被引数:5.9万
M
Matthew Mei
H 指数:33论文数:278被引数:3,972
A
Alex F. Herrera
H 指数:46论文数:565被引数:1.1万
N
Nancy L. Bartlett
H 指数:96论文数:937被引数:4.7万
L
Larry W. Kwak
H 指数:73论文数:563被引数:1.9万
T
Tanya Siddiqi
H 指数:52论文数:462被引数:2.1万
L
Leslie Popplewell
H 指数:47论文数:404被引数:1.0万
F
Frederick L. Locke
H 指数:61论文数:865被引数:3.2万
O
Olalekan O. Oluwole
H 指数:49论文数:375被引数:2.0万
J
John H. Baird
H 指数:15论文数:132被引数:2,002